Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q3 2023 · 10-Q
Revenue$388.45K$388.45K−95.8% vs Q3 2022 Net Income-$33.93M-$33.93MN/M vs Q3 2022 EPS Diluted-$1.52-$1.52N/M vs Q3 2022 Operating Income-$35,553,012N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$29,110,632N/M Margins · derivedOperating margin-9152.6%−8762.0 pt vs Q3 2022
Net margin-8734.8%−8322.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end